Marthanoir
TB Fanatic
The European Union's medicines regulator has said it is reviewing reports of a bleeding condition in people after receiving AstraZeneca's Covid-19 vaccine and looking into Janssen's jab over reports of rare blood clots.
While Anglo-Swedish drugmaker AstraZeneca has been caught in a turmoil over possible links to rare blood clots in the brain and abdomen, and subsequent restriction on usage of its vaccine, this is a formal disclosure of the Janssen probe.
Four serious cases of rare blood clots with low platelets, one of which was fatal, have been reported after inoculation with Johnson & Johnson's vaccine from its Janssen unit, the European Medicines Agency (EMA) said.
It said five cases of capillary leak syndrome linked to AstraZeneca's vaccine were reported. The condition, in which blood leaks from the smallest of vessels into muscles and body cavities, is characterised by swelling and a drop in blood pressure.
However, the EMA has said that “at this stage, it is not yet clear whether there is a causal association” between the vaccines and the reported conditions.
The EMA gave approval to the Janssen vaccine in early March, with Ireland expecting its first delivery later this month. By June more than 600,000 doses will have arrived in the country.
A total of 2.19 million Janssen jabs have been secured under purchasing agreements for this year; enough to vaccinate half the Irish population.
AstraZeneca and US-based J&J did not immediately respond to requests for comments.
www.breakingnews.ie
While Anglo-Swedish drugmaker AstraZeneca has been caught in a turmoil over possible links to rare blood clots in the brain and abdomen, and subsequent restriction on usage of its vaccine, this is a formal disclosure of the Janssen probe.
Four serious cases of rare blood clots with low platelets, one of which was fatal, have been reported after inoculation with Johnson & Johnson's vaccine from its Janssen unit, the European Medicines Agency (EMA) said.
It said five cases of capillary leak syndrome linked to AstraZeneca's vaccine were reported. The condition, in which blood leaks from the smallest of vessels into muscles and body cavities, is characterised by swelling and a drop in blood pressure.
However, the EMA has said that “at this stage, it is not yet clear whether there is a causal association” between the vaccines and the reported conditions.
The EMA gave approval to the Janssen vaccine in early March, with Ireland expecting its first delivery later this month. By June more than 600,000 doses will have arrived in the country.
A total of 2.19 million Janssen jabs have been secured under purchasing agreements for this year; enough to vaccinate half the Irish population.
AstraZeneca and US-based J&J did not immediately respond to requests for comments.
EU reviews possible link between Janssen vaccine and rare blood clots | BreakingNews.ie
Four serious cases of rare blood clots with low platelets have been reported after inoculation with Johnson & Johnson's vaccine
www.breakingnews.ie
